HOLLISTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Sidoti August Virtual Investor Conference on August 16, 2023. Joining him will be Jennifer Cote, the company’s Chief Financial Officer and Treasurer.
The presentation will begin at 11:30 a.m. ET on Wednesday, August 16th and can be accessed live here. The presentation will also be archived on the Investor Relations section of the Harvard Bioscience website for a limited period of time.
Harvard Bioscience will also host virtual one-on-one meetings with investors on Wednesday August 16 and Thursday August 17. To register for the presentation or to schedule a one-on-one meeting, please visit www.sidoti.com/events.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Investor Contact:
Harvard Bioscience, Inc.
Investor Relations
(508) 893-3120
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.32 |
Daily Change: | -0.0082 -2.48 |
Daily Volume: | 23,783 |
Market Cap: | US$14.050M |
February 24, 2025 November 07, 2024 October 03, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load